AzTrials
AzTrials

Fluid OverloadTIDENCT07275658

Timing and Dose of Fluid Deresuscitation in Critically Ill Patients

An observational study of Fluid Overload and Critical Care, Intensive Care, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 2 sites in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Fluid deresuscitation is an important intervention in the Intensive Care Unit (ICU). This study aims to find (1) determinants of successful deresuscitation, (2) the optimal rate (dose) of deresuscitation based on these determinants, and (3) differences in metabolic profiles for a more personalized approach of… Read more about this study

Who is it for?
Ages 18 years and older
How many people
150 participants
Where
2 sitesNetherlands
Study dates
15 Oct 2025to 28 Feb 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients admitted to the Intensive Care Unit

Who may be able to join

  • Admission to one of the participating ICUs;
  • Clinical indication for deresuscitation using diuretics or ultrafiltration as set by the treating physician; first attempt during the ICU stay.

Who cannot join

  • Age below 18 years old;
  • Major cardiac shunts;
  • Moderate to severe aortic regurgitation;
  • Morbid Obesisty (BMI >40);
  • POCUS impossible or unreliable (i.e. pre-existing interstitial lung disease);
  • PLR or modified form of PLR impossible (i.e. ECMO);
Show all 10Show fewer
  • Transfer from another ICU;
  • Previous inclusion in this study;
  • Patients who are moribund or facing the end of life;
  • Opt out.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Santje A.S. Slot, MD contact

s.a.s.slot@olvg.nl

Netherlands2 sites, 2 recruiting
  • OLVG

    Amsterdam, 1091AC

    Santje A.S. Slot, MD, +31 (0)20 599 9111, s.a.s.slot@olvg.nl

    Recruiting
  • Amsterdam UMC

    Amsterdam, 1105AZ

    Krijna Opschoor, MD, +31 (0)20 566 9111, k.opschoor@amsterdamumc.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: Timing and Dose of Fluid Deresuscitation in Critically Ill Patients: a Prospective Observational Multicenter Study

Fluid deresuscitation is an important intervention in the Intensive Care Unit (ICU). This study aims to find (1) determinants of successful deresuscitation, (2) the optimal rate (dose) of deresuscitation based on these determinants, and (3) differences in metabolic profiles for a more personalized approach of deresuscitation.

This study is a multicenter, prospective, observational cohort study in critically ill patients. This study will include ICU patients who have a clinical indication for deresuscitation as set by the treating physician. Clinical, ultrasound and laboratory values will be collected and used for analysis.

Read the detailed description

Primary objective:

The aim of this study is to identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours without hemodynamic consequences.

Secondary objectives:

  • Timing of deresuscitation:
  • Identify determinants of successful deresuscitation in ICU patients, defined as achieving a negative fluid balance within 24 hours;
  • Compare these determinants with determinants for the clinical decision of deresuscitation by the treating physician;
  • Identify differences in these determinants within subgroups of sepsis, ARDS and cardiac patients, provided the numbers are sufficient;
  • Rate (dose) of deresuscitation:
  • Identify parameters associated with diuretic or natriuretic response during deresuscitation;
  • Find individualized optimal rates of deresuscitation based on these determinants;
  • Possible complications of deresuscitation:
  • Determine whether there is an association between electrolyte or acid-base disturbances during deresuscitation (e.g. the Strong Ion Difference) and clinical outcomes;
  • Determine whether there is an association between the rate of deresuscitation and hemodynamic consequences;
  • Determine whether there is an association between the timing and rate of deresuscitation and atrial fibrillation (AF);
  • Determine whether there is an association between deresuscitation and the occurrence of delirium;
  • Determine whether there is an association between timing and rate of deresuscitation and acute kidney injury (AKI).

Study design:

The TIDE study is a multicenter, prospective, observational cohort study in the ICUs of the Amsterdam UMC and OLVG in Amsterdam, the Netherlands.

Study population:

Adult patients admitted to the ICU, who have a clinical indication for deresuscitation as set by the treating physician, using diuretics or ultrafiltration; first deresuscitation attempt during the ICU stay.

Sample size calculation:

For finding associations with logistic regression with a moderate (odds ratio >1.5) to strong (odds ratio >2.5) effect an alpha set at 0.05, power set at 0.8 and an estimated failure of 50% or more, we would need a sample size of around 150-210 patients.

Methods:

Patients in the participating ICUs are screened for eligibility when the treating physician sets a clinical indication for deresuscitation. Eligible patients will be included in the study. At that time, defined as baseline, clinical, ultrasound and laboratory measures will be collected. Clinical measures among others include: heart rate, mean arterial pressure, dose of vasopressors, and capillary refill time. Ultrasound measurements include: lung ultrasound scores (LUS), venous excess ultrasound (VExUS), and cardiac ultrasound, including VTI during a passive leg raise (PLR). Laboratory measurements include arterial blood gas analysis and urinalysis. Furthermore, baseline characteristics such as demographics, reason for ICU admission, severity of illness scores, and medical history are collected.

Deresuscitation will be performed according to standard care according to the treating physician's insights. Primary follow up is 24 hours in which granular data of deresuscitation tactics, deresuscitation output, electrolyte and acid-base disturbances, and hemodynamic consequences are collected. Secondary follow up is at 7 days for complications such as acute kidney injury and at 28 days for mortality, ICU length of stay (LOS) and ventilator free days (VFD), where available.

Keywords
ultrasound, RRT, furosemide
Medical subject headings
Edema

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Successful deresuscitation without hemodynamic consequences

    Reach negative fluid balance in first 24 hours without hemodynamic consequences (yes/no), defined as either hypotension or hypoperfusion:

    1. Hypotension
    • Interventions required to maintain blood pressure MAP > 65mmHg
    • Deresuscitation is stopped
    • Fluid bolus needs to be given
    • Noradrenaline (or other vasopressor) needs to be initiated, increased to > 0.2 microg/kg/min, or increased by 50%
    • Dose reduction or interruption of RRT
    1. Hypoperfusion (one of the following):
    • Arterial lactate level >3 and/or increased 25% or more
    • New development of mottled skin
    • Capillary refill time > 3 seconds
    • New oliguria (urine output < 0.3-0.5ml/kg/hour for the previous 6 hours)

    Measured: 24 hours

Secondary outcomes (16)
  1. Successful deresuscitation

    Reach negative fluid balance in the first 24 hours

    Measured: 24 hours

  2. Rate of deresuscitation

    Urine output or ultrafiltration rate in mL/kg/h

    Measured: 24 hours

  3. Dose of deresuscitation

    Fluid balance in mL/kg

    Measured: 24 hours

  4. Natriuresis

    Urinary sodium output in mmol/L/24h

    Measured: 24 hours

  5. Delta Strong Ion Difference

    ΔSID in mmol/L

    Measured: 24 hours

  6. Delta serum sodium

    Serum ΔNa in mmol/L

    Measured: 24 hours

  7. Delta serum chloride

    Serum ΔCl in mmol/L

    Measured: 24 hours

  8. Atrial fibrillation

    Occurrence of ≥1 hour AF or AF for which treatment is needed during the deresuscitation window if not present at baseline

    Measured: 24 hours

  9. Acute Kidney Injury (AKI)

    AKI as diagnosed based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria:

    Stage 1: sCreat 1.5-1.9 times baseline OR ≥0.3 mg/dl (≥26.5 mmol/l) increase OR urine output <0.5 ml/kg/h for 6-12 hours Stage 2: sCreat 2.0-2.9 times baseline OR urine output <0.5 ml/kg/h for ≥12 hours Stage 3: sCreat 3.0 times baseline OR Increase in serum creatinine to ≥4.0 mg/dl (X353.6 mmol/l) OR Initiation of renal replacement therapy OR urine output <0.3 ml/kg/h for ≥24 hours OR anuria for ≥ 12 hours

    Measured: 7 days

  10. Persistent AKI

    Prolonged AKI for ≥48 hours if not present before start deresuscitation

    Measured: 7 days

  11. Renal Replacement Therapy (RRT)

    Need for RRT after start deresuscitation if not used at baseline and primary deresuscitation

    Measured: 7 days

  12. Delirium

    Need 1 or more types of medication to treat delirium after start deresuscitation

    Measured: 7 days

  13. ICU-mortality

    Mortality within ICU stay

    Measured: 28 days

  14. 28-day mortality

    Mortality after 28 days

    Measured: 28 days

  15. Ventilator free days (VFD)

    Patient is alive and breathes without assistance of the mechanical ventilator, if the period of unassisted breathing lasted at least 24 consecutive hours:

    • VFD-28 = 0 if subject dies within 28 days of mechanical ventilation
    • VFD-28 = 28 - x if successfully liberated from ventilation x days after initiation successful liberation: extubation (planned or unplanned) without death or reintubation within the next 72 hours
    • VFD-28 = 0 if the subject is mechanically ventilated for ≥ 28 days

    Measured: 28 days

  16. ICU length of stay (LOS)

    Length of stay in the intensive care unit

    Measured: 28 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2025
  2. Study start15 Oct 2025
  3. Primary completion31 Jan 2027 (estimated)
  4. Study completion28 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07275658
Sponsor's protocol ID
2025.0391
Acronym
TIDE
Status last verified
Nov 2025
First submitted
28 Nov 2025
Last updated
21 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Fluid Overload and Critical Care, Intensive Care, run by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) at 2 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Krijna Opschoor, MD (+31 (0)20 566 9111, k.opschoor@amsterdamumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Successful deresuscitation without hemodynamic consequences (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in